Skip to content

Safety and Efficacy Assessment of Using the zLOCK Facet Stabilization System

Safety and Efficacy Assessment of Using the zLOCK Facet Stabilization System

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05266521
Enrollment
80
Registered
2022-03-04
Start date
2021-11-07
Completion date
2025-09-30
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Keywords

Stabilization, Facet arthritis, Spondylolisthesis, Stenosis

Brief summary

The zLOCK Facet Stabilization System is a fixation device intended to provide posterior stability in the lumbar spine fusion procedure. The system can be placed either as an adjunct to an inter-vertebral anterior cage or as stand-alone with/ without additional decompression of the dural sac or nerve roots as appropriate for the specific patient and surgeon's discretion. The zLOCK implant is placed inside the facet to stabilize the motion and enhance the bony fusion of the joint. The zLOCK Facet Stabilization System is intended for single-level stabilization of a spinal motion segment in order to promote bony fusion of the joint. The zLOCK system is indicated for use from L1-L2 to L5-S1 joints. The zLOCK implant is inserted into the facet joint space while adapting to the joint's changing geometry. Stabilization is achieved by a firm grip of each joint bone and resisting any relative motion. The zLOCK implant is placed percutaneously and requires only one incision per side, thereby reducing the invasiveness procedure duration and shortening the recovery period. This pivotal study was designed in order to assess the safety and effectiveness of the zLOCK system.

Interventions

zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains

Sponsors

ZygoFix
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patient is scheduled for spine surgery with at least one of the following: * Degenerative Spondylolisthesis grade 1; * Mild to Moderate stenosis; * Degeneration of the facets. 2. When used stand-alone disc height should be maximum 50% of the adjacent disc height. 3. 18\< Age \<75 4. Weight \< 100Kg 5. Signed informed consent form 6. At least 3 months of unsuccessful conventional treatments

Exclusion criteria

1. Fusion procedure performed or required in more than one motion segment. 2. Acute or chronic spinal infections. 3. Osteoporosis when used in adjunct to an anterior interbody cage (DEXA \< -2.5). 4. Absence of posterior spinal elements including the pedicle, pars interarticularis, facet joints, spinous process and the majority of the lamina which make it unstable or not possible to place. 5. Any entity or conditions that totally preclude the possibility of fusion, i.e. cancer or kidney dialysis. 6. Obesity (BMI ≥30) 7. Unilateral application of device, except in combination with anterior interbody cages. 8. Known sensitivity to Titanium. 9. Alcoholism, or drug abuse 10. Subject with a cardiac pacemaker or other implanted electro medical device 11. Women who are either pregnant or nursing at the time of screening (to be verified by test in case of woman of child-bearing potential that do not practice medically acceptable methods of contraception) 12. Concurrent participation in another clinical trial using any investigational drug or device. 13. Mental disorders. 14. Tumor 15. Fracture or other instabilities of the posterior elements.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Treatment-Emergent Adverse Events as assessed by paucity of device related reoperation3 monthsThe safety of the zLOCK Facet Implant System will be established based on the paucity of device-related reoperations.

Secondary

MeasureTime frameDescription
Change in pain level measured by Visual Analog Score for pain1 yearThe efficacy assessment of the ZygoFix Facet stabilization System will be established by change in pain level .

Countries

Germany, Italy

Contacts

Primary ContactHanna Levy, Dr.
hanna@qsitemed.com+972522824966

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026